Cefuroxime is one of the most widely used cephalosporin antibiotics. It possesses a broad antimicrobial spectrum, including most clinically significant "community-acquired" bacterial pathogens.

Cefuroxime is effective against penicillin-resistant pneumococci and staphylococci, making it a drug of choice for antimicrobial therapy in cases of community-acquired pneumonia and skin and soft tissue infections. It also has a bactericidal effect against enterobacteria (including ampicillin-resistant strains), which are pathogens of urinary tract infections and "community-acquired" intra-abdominal infections. When combined with aminoglycosides, a pronounced synergistic effect is observed.

Cefuroxime powder for preparing a solution for intramuscular injection produced by PJSC "Kraspharma" is designed to optimize antibiotic therapy both in hospital and outpatient settings, as administering intramuscular injections does not require the patient to stay in the hospital under the supervision of qualified medical staff.

This drug is indicated for use in both adults and children for the following conditions:

• Lower respiratory tract infections, such as bacterial pneumonia, acute bacterial bronchitis, exacerbation of chronic bronchitis, infected bronchiectasis, lung abscess, postoperative infections of the thoracic organs.
• ENT infections, such as otitis media, sinusitis, tonsillitis, pharyngitis.
• Urinary tract infections, such as acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria.
• Gonorrhea.
• Skin and soft tissue infections, such as cellulitis, erysipelas, and wound infections.
• Bone and joint infections, such as osteomyelitis and septic arthritis.
• Obstetric and gynecological infections, such as pelvic inflammatory disease.
• Other infections, including peritonitis.
• Prevention of infectious complications during surgery on abdominal organs, the pelvic region, orthopedic surgeries, and surgeries on the heart, lungs, esophagus, and vessels—situations where there is an increased risk of infectious complications.

When necessary, the intramuscular form of cefuroxime can be used as part of step-down therapy, transitioning to oral administration of cefuroxime axetil, mainly for the treatment of pneumonia and exacerbations of chronic bronchitis.

To prevent pain associated with intramuscular injection, Cefuroxime powder for solution for intramuscular injection is available in a form that includes a solvent—Lidocaine solution for injection (10 mg/ml, 3.5 ml ampoule).